Tumor Regression Patterns in Retinoblastoma. | [Journal of College of Physicians and Surgeons--Pakistan : JCPSP • 2016]

Author(s):

1. Saemah Nuzhat Zafar: Department of Pediatric Ophthalmology, Al-Shifa Trust Eye Hospital, Rawalpindi, Pakistan

2. Sorath Noorani Siddiqui: Department of Pediatric Ophthalmology, Al-Shifa Trust Eye Hospital, Rawalpindi, Pakistan

3. Naima Zaheer: Department of Pediatric Ophthalmology, Al-Shifa Trust Eye Hospital, Rawalpindi, Pakistan

Abstract:

Objective: To observe the types of tumor regression after treatment, and identify the common pattern of regression in our patients. Study Design: Descriptive study. Place and Duration of Study: Department of Pediatric Ophthalmology and Strabismus, Al-Shifa Trust Eye Hospital, Rawalpindi, Pakistan, from October 2011 to October 2014. Methodology: Children with unilateral and bilateral retinoblastoma were included in the study. Patients were referred to Pakistan Institute of Medical Sciences, Islamabad, for chemotherapy. After every cycle of chemotherapy, dilated fundus examination under anesthesia was performed to record response of the treatment. Regression patterns were recorded on RetCam II. Results: Seventy-four tumors were included in the study. Out of 74 tumors, 3 were ICRB group A tumors, 43 were ICRB group B tumors, 14 tumors belonged to ICRB group C, and remaining 14 were ICRB group D tumors. Type IV regression was seen in 39.1% (n=29) tumors, type II in 29.7% (n=22), type III in 25.6% (n=19), and type I in 5.4% (n=4). All group A tumors (100%) showed type IV regression. Seventeen (39.5%) group B tumors showed type IV regression. In group C, 5 tumors (35.7%) showed type II regression and 5 tumors (35.7%) showed type IV regression. In group D, 6 tumors (42.9%) regressed to type II non-calcified remnants. Conclusion: The response and success of the focal and systemic treatment, as judged by the appearance of different patterns of tumor regression, varies with the ICRB grouping of the tumor.

Page(s): 896-899

DOI: DOI not available

Published: Journal: Journal of College of Physicians and Surgeons--Pakistan : JCPSP, Volume: 26, Issue: 11, Year: 2016

Keywords:

Keywords are not available for this article.

References:

[1] ShieldsCL,ShieldsJA, 2010.Retinoblastoma management: advances in enucleation, intravenous chemoreduction, and intra-arterial chemotherapy,Curr Opin Ophthalmol 21 203 -12

[2] ShieldsCL,KalikiS,RojanapornD,Al-DahmashS,BianciottoCG,ShieldsJA, 2012.Intravenous and intra-arterial chemotherapy for retinoblastoma: What have we learned,Curr Opin Ophthalmol 23 202 -9

[3] GhassemiF,RahmanikhahE,RoohipoorR,KarkhanehR,FaeghA, 2013.Regression patterns in treated retinoblastoma with chemotherapy plus focal adjuvant therapy,Pediatr Blood Cancer 60 599 -604

[4] ShieldsCL,MashayekhiA,AuAK, 2006.The international classification of retinoblastoma predicts chemoreduction success,Ophthalmology 113 2276 -80

[5] SinghA,DamatoB, 2007.Staging and grouping of retinoblastoma,Clinical Ophthalmic Oncology. Philadelphia: Saunders Elsevier 422 -7

[6] RamasubramanianA,ShieldsCL,RamasubramanianA,ShieldsCL, 2012.Epidemiology and magnitude of the problem,Retinoblastoma. New Delhi: Jaypee Brothers Medical Publishers 10 -5

[7] ShieldsJA,ShieldsCL,ShieldsJA,ShieldsCL, 2008.Retinoblastoma,Intraocular tumors. An atlas and textbook. 2nd ed. Philadelphia, PA: Lippincott Williams Wilkins 293 -365

[8] IslamF,ZafarSN,SiddiquiSN,KhanA., 2013.Clinical course of retinoblastoma,J Coll Physicians Surg Pak 23 566 -9

[9] ZhaoJ,LiS,ShiJ,WangN., 2011.Clinical presentation and group classification of newly diagnosed intraocular retinoblastoma in China,Br J Ophthalmol 95 1072 -6

[10] ShieldsCL,FulcoEM,AriasJD,AlarconC,PellegriniM,RishiP, 2013.Retinoblastoma frontiers with intravenous, intraarterial, periocular, and intravitreal chemotherapy,Eye (Lond) 27 253 -64

[11] KimJM,KimJH,KimSJ,ParkKD,ShinHY,AhnHS, 2010.Visual prognosis of retinoblastoma in the posterior pole treated with primary chemotherapy plus local treatment,Korean J Ophthalmol 24347 -52

[12] VajzovicLM,MurrayTG,Aziz-SultanMA,ScheflerAC,WolfeSQ,HessD, 2011.Supraselective intra-arterial chemotherapy: evaluation of treatment-related complications in advanced retinoblastoma,Clin Ophthalmol 5 171 -6

[13] ShieldsCL,BianciottoCG,RamasubramanianA,LallySE,JabbourP,GriffinGC, 2011.control of tumor, subretinal seeds, and vitreous seeds,Arch Ophthalmol 129 1399 -1406

[14] MunierF,GaillardMC,BalmerA,SolimanS,PodliskyG,MoulinAP, 2012.Intravitreal chemotherapy for vitreous disease in retinoblastoma revisited: From prohibition to conditional indications,Br J Ophthalmol 96 1078 -83

[15] GhassemiF,ShieldsCL, 2012.Intravitreal melphalan for refractory or recurrent vitreous seeding from retinoblastoma,Arch Ophthalmol 130 1268 -71

[16] KivelaT., 2009.The epidemiological challenge of the most frequent eye cancer: Retinoblastoma, an issue of birth and death,Br J Ophthalmol 93 1129 -31

[17] PalamarM,ThangappanA,ShieldsCL, 2011.Evolution in regression patterns following chemoreduction for retino-blastoma,Arch Ophthalmol 129 727 -30

[18] XueK,QianJ,YueH,YuanYF,ZhangR, 2012.Retinoblastoma regression patterns and results following chemoreduction and adjuvant therapy,Zhonghua Yan Ke Za Zhi 48 625 -30

[19] DemirciH,EagleRC,JrShieldsCL,ShieldsJA, 2003.Histopathologic findings in eyes with retinoblastoma treated only with chemoreduction,Arch Ophthalmol 121 1125 -31

Citations

Downloads

Views